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Abstract
Distinguishing the driver mutations from somatic mutations in a tumor genome is one of the major challenges of
cancer research. This challenge is more acute and far from solved for non-coding mutations. Here we present
OncodriveFML, a method designed to analyze the pattern of somatic mutations across tumors in both coding and
non-coding genomic regions to identify signals of positive selection, and therefore, their involvement in tumorigenesis.
We describe the method and illustrate its usefulness to identify protein-coding genes, promoters, untranslated regions,
intronic splice regions, and lncRNAs-containing driver mutations in several malignancies.
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Background
Massive cancer genomic initiatives promoted by the
advance of next generation sequencing technologies
have uncovered the landscape of somatic mutations in
cohorts of patients suffering from dozens of the most
common tumor types [1, 2]. These initiatives, focused
mostly on exome regions, demonstrated the pressing
need to develop methods to identify protein-coding can-
cer drivers from the wealth of mutated genes in tumor
genome [3]. Several methods that identify genes whose
mutational patterns significantly deviate from the
expected behavior have been developed and validated
[3–8]. These abnormal mutational patterns are caused
by positive selection acting on the mutations in driver
genes during the course of tumorigenesis and tumor
evolution [9]. A mutational frequency across a cohort of
tumors that is significantly higher than the background
mutation rate is the most intuitive and exploited signal
of positive selection, implemented for example by com-
putational approaches such as MuSiC [8] and MutSig
[4]. Nevertheless, the correct estimation of the back-
ground mutation rate of protein-coding genes requires
accounting for many known—and probably also yet
unknown—covariates, some of which can currently only
be approximated [10]. In 2012 we introduced a compu-
tational approach to detect a different signal of positive
selection in driver genes: the bias towards the accumula-
tion of high impacting mutations [5] across tumor
samples. We proved that the top-ranking genes in their
deviation of the average impact score of mutations
observed from the expected average impact score of the
same number of mutations in the given cohort—func-
tional mutation (FM) bias—were bona fide cancer
drivers.
Currently, the availability of hundreds of whole-
genome sequences from tumors presents us with the
unprecedented opportunity of identifying non-coding
genomic regions involved in cancer development upon
somatic mutations. Most of the approaches developed to
scan protein-coding genes involved in tumorigenesis
cannot be readily extended to the analysis of non-coding
regions [3], and only few approaches designed to detect
non-coding drivers have been recently proposed [11–14].
Moreover, catalogs of somatic mutations detected by
targeted sequencing specific regions of genomes are
accumulating as genome sequencing becomes routine in
the clinical practice of oncology. The Memorial Sloan
Kettering-Integrated Mutation Profiling of Actionable
Cancer Targets (MSK-IMPACT) [15], for example, has
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carried out the targeted deep sequencing of all exons
and selected introns of 341 key cancer genes of thou-
sands of tumors every year (https://www.sloanketter-
ing.edu/blog/expanding-impact-precision-medicine-fuel-
discoveries). Most current methods to detect drivers
rely on whole-exome or whole-genome sequencing
data to build their background models for analysis.
Therefore, they are unable to mine this rich data
accumulating from targeted sequencing to further
pinpoint the regions within cancer genes that ex-
hibit signals of positive selection in different tumor
types.
Here we propose a novel approach, OncodriveFML, to
estimate the accumulated functional impact (FI) bias of
tumor somatic mutations in genomic regions of interest,
both coding and non-coding, based on a local simulation
of the mutational processes affecting it. OncodriveFML
possesses two critical advantages over the current gener-
ation of methods aimed at identifying cancer drivers.
First, it can directly compute the FM bias—and thus
identify drivers—of any genomic element, provided only
that a score to assess the FI of somatic mutations can be
computed for that element. In the “Results” section, we
illustrate this versatility by employing different FI scor-
ing approaches to detect putative cancer drivers among:
(1) coding genes; (2) intronic splicing regions; (3) pro-
moter regions; (4) untranslated regions (UTRs) of mes-
senger RNAs (mRNA); and (5) long non-coding RNAs
(lncRNAs). This feature will prove crucial as more
cohorts of cancer tumors are sequenced at the whole-
genome range opening up the possibility to detect non-
coding elements involved in tumorigenesis. Second, the
FM bias of genomic elements can still be computed if
only one or few of them have been sequenced across the
cohort of patients, as is the case of targeted sequencing
aimed at informing clinical decision-making. This raises
the possibility of dramatically lowering the cost of
sequencing cohorts of tumors to carry out analyses such
as the identification of genes involved in specific cancer-
related processes, such as drug resistance, metastasis,
and tumor relapse. We provide the source code of a web
server to detect putative driver genomic elements, both
coding and non-coding on mutations data from cohorts
of tumors using OncodriveFML (http://www.intogen.
org/oncodrivefml).
Results
OncodriveFML computes a local FM bias
The rationale behind OncodriveFML is that the observa-
tion of somatic mutations on a genomic element (coding
gene, promoter, UTR, lncRNA, etc) across tumors,
whose average impact score is significantly greater than
expected for said element constitutes a signal that these
mutations have undergone positive selection during
tumorigenesis. This, in turn is considered as a direct
indication that this element drives tumorigenesis. We
call this deviation of the observed average impact
score of somatic mutation in a genomic feature from
its expected value, the functional mutation bias, or
FM bias. To measure the FM bias of a particular
element, OncodriveFML is required to: (1) be able to
compute a relevant score of the predicted impact of
the mutations in the genomic element; and (2) simulate
the mutational processes to compute the expected
average impact score.
Any approach to compute the impact of mutations,
however different depending on the type of genomic
element under analysis, may serve the purpose of com-
puting its observed FM bias (Fig. 1a). For instance, in
mutations in protein-coding genes, one could measure
the predicted impact on protein structure and function,
while in RNA genes or UTRs, one could compute the
impact of the mutations on RNA secondary structure,
which is known to be key to their function. Also in
UTRs, a useful measure of the FI of mutations could be
their effect on the binding of microRNAs (miRNAs) to
their target sites. In the case of promoters and en-
hancers, the effect of mutations on existing transcription
factor binding sites or the creation of new ones may be
assessed. Combined scores that take into account several
features to measure the FI, such as CADD [16], may also
be useful. The only requirements of the FI scoring
approach is that it is relevant for the function of the gen-
omic element under study and that it can be computed
for all possible mutations in the element. Here we
present implementations of OncodriveFML that use
several FI scoring metrics.
OncodriveFML consists of three steps illustrated in
Fig. 1b–d. In the first step, the average FI score of the
set of somatic mutations observed in the element of
interest across a tumor cohort is computed (Fig. 1b). In
the second step, sets of mutations of the same size as
the number of mutations observed in the element are
randomly sampled from the universe of all the variants
that it can possibly sustain (Fig. 1c). To accurately model
mutational processes in the tumor type of interest, the
sampling is done following the probability of mutation
of different tri-nucleotides, which can either be com-
puted from the mutations observed in each sample, in
cohort under analysis as a whole, or pre-computed from
previously analyzed tumor cohorts of the same or similar
type. This random sampling is iterated a number of
times (e.g. 10,000 times) to generate local expected aver-
age impact scores. Finally, OncodriveFML compares the
average impact score observed for each element to its
local expected average impact score resulting from the
sampling and computes a local FM bias, in the form of
an empirical p value which measures the deviation of
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the observed average score from the expected back-
ground (Fig. 1d). Elements with significant local FM bias
after the correction for false discovery rate are deemed
likely drivers.
OncodriveFML detects driver coding genes
To test its validity, we applied OncodriveFML to the de-
tection of drivers among all human protein-coding genes
using the set of somatic mutations detected by whole-
exome sequencing across the tumors of 19 cohorts,
(these and all datasets of somatic mutations employed
here are described in Additional file 1). First, through
quantile-quantile (QQ) plots comparing the expected
and observed distribution of the FM bias p values (Fig. 2a
and Additional file 2, section A), we demonstrate that
the latter follows the expected homogeneous distribution
of the null hypothesis, with the exception of the few
cases that correspond to genes with significant FM bias.
Among the top ranking genes identified by Oncodri-
veFML in the four cohorts presented as examples in
Fig. 2b and c, there are well-known cancer genes, such
as TP53, KEAP1, ARID2, and RUNX1. Mutations
observed in these genes exhibit a clear bias towards high
FI (Fig. 2b; whole list in Additional file 3).
Second, as a proxy of the true positives rate of the
method, we computed the fold enrichment in the pro-
portion of known cancer genes (genes in the Cancer
Gene Census (CGC) [17]) among its top ranking genes.
We found that OncodriveFML performs better in this
metric than the original version of OncodriveFM [5],
MutSigCV [4], and e-Driver [18] (Fig. 2c and Additional
file 2, section A) across the 19 cohorts of tumors ana-
lyzed. We also compared the results of OncodriveFML
with a newer version of MutSigCV run by its authors
[19], finding that there is an important overlap between
the genes identified by both methods and that each
method identifies additional true cancer genes missed by
the other, stressing the complementarity of the two
approaches (Additional file 2, section A). We next ap-
plied the OncodriveFML FM bias test to randomized
datasets of mutations, built by reshuffling the mutations
observed within each genome, following the rates of tri-
nucleotides and the constraints of number of mutations
per sample and per region. The number of genes de-
tected as putative drivers within these random datasets
of mutations would act as a proxy of the rate of false
positive elements detected by the FM bias test. We car-




Fig. 1 The OncodriveFML approach to detect signals of positive selection. a The functional impact (FI) of mutations may be computed in different
manners for different types of genomic elements. b The FI of somatic mutations occurring in a genomics element across tumors are computed.
c Mutation sets are randomly sampled from the element under analysis and the FI score of each simulated mutation is obtained. d The mean FI of the
mutations observed in the element (red dots) is compared to the distribution of FI means of randomly generated mutations (violin plots) to obtain an
empirical p value. On the left is shown an example of highly significant p value while the violin plot on the right illustrates a non-significant case
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Fig. 2 Results of the application of OncodriveFML to identify driver protein-coding genes across four cohorts of tumors. a Quantile-quantile
(QQ) plots comparing the expected and observed distribution of FM bias p values of genes. Gray dots denote p values obtained on the randomized
dataset that serves as negative control. Names in red indicate genes with FM bias q-value below 0.1, while names in black indicate genes with FM bias
q-value below 0.25. Names in bold denote genes annotated in the Cancer Gene Census (CGC). b Mutation needle-plots showing the distribution of
mutations along the sequences of the CDS of selected genes. The color of the circles follows the FI CADD score scale. The y-axis indicates the number
of tumor samples in the cohorts where mutations at each position have been observed. The behavior of the CADD FI score across the entire CDS is
shown below the needle-plot. c Fold increase in the proportion of CGC genes among sets with increasing number of top ranking genes detected by
four methods: OncodriveFML, OncodriveFM, MutSigCV, and e-Driver. (See details in the text.) QQ plots and fold CGC proportion increase graphs for
other 15 cohorts of tumors are available in Additional file 2, section A
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tumors that constitute the WE-4482 dataset. Oncodri-
veFML finds no significant gene in this dataset (gray
dots in Fig. 2a), as expected for an accurate method with
a low number of false positives. The whole list of driver
candidates appears in Additional file 3. Taken together,
the results presented in this section demonstrate that
OncodriveFML identifies putative protein-coding driver
genes with a sensitivity that outperforms five widely
employed methods developed for this task, while main-
taining a very low false positive rate.
OncodriveFML detects driver non-coding elements
One of the most interesting features of OncodriveFML
is its applicability to the detection of driver non-coding
genomic element. Therefore, we next tested its perform-
ance in the identification of putative driver promoter, 5′
UTR, splice intronic, and 3′ UTR regions of coding
genes containing mutations across 22 tumor cohorts
with whole-genome data sequenced by TCGA [12] or
other projects [20] (datasets WG-505 and WG-608,
respectively, in Additional file 1), as well as two pan-
cancer cohorts resulting from pooling the mutations de-
tected in all cohorts of each dataset (Figs. 3 and 4). Our
primary aim was to test OncodriveFML at the identifica-
tion of putative driver non-coding elements and com-
pare its performance with other two recently published
methods to the same effect [13, 14]. Due to the complete
absence of a curated gold standard of non-coding driver
elements, we limited the comparison to the assessment
of the rate of false positives detected by each method
through the analysis of the QQ plots of their observed
and expected distributions of p values and the analysis
of randomized datasets. We used CADD to score the FI
of mutations occurring in all aforementioned non-
coding elements, with the exception of 3′ UTRs, where
we used the score provided by RNAsnp to that effect
(see below). As with coding genes, the observed and
expected distributions of the FM bias p values of the
22—and pan-cancer—cohorts correlate very well, and
when applied to randomized mutation dataset it shows a
good control of false positives (Fig. 3a). In this regard,
OncodriveFML compares favorably with two recently
published methods in the identification of putative non-
coding elements across the cohorts of both the WG-505
and the WG-608 datasets (Additional file 2, section B).
In the following sections, we describe in detail the most
interesting candidate drivers of each type of non-coding
elements identified as significantly FM biased.
OncodriveFML uncovers putative driver promoters
and 5′ UTRs
In the pan-cancer cohort, comprising 505 tumors the
promoter regions with the most significant FM bias
comprise a shortlist of interesting candidate drivers,
such as those of TERT (details in Fig. 3b), SYF2,
ARGHEF18, and POLR2D. TERT encodes the reverse
transcriptase subunit of telomerase required to maintain
telomere length during tumor growth. Activating muta-
tions in TERT promoter have been found as drivers in
multiple types of cancer [12, 21, 22]. Other promising
novel candidates include the promoters of SYF2 (details
in Fig. 3c), an mRNA splicing factor thought to interact
with a cell cycle regulator [23], ARHGEF18, a Rho-
specific guanine nucleotide exchanging factor involved
in RhoA activation and cell motility [24], and POLR2D
(Fig. 3d), a subunit of the RNA polymerase, which
contains mutations very close to the transcription start
site (TSS) in melanoma samples [25, 26].
In a cohort of 18 lower grade gliomas, in addition to
the TERT promoter, OncodriveFML identifies the pro-
moter of SPN with a highly significant FM bias (Fig. 3e).
The expression of both genes is significantly higher in
samples bearing mutations in their promoters than in
non-mutated samples (Fig. 3f ), which provides founda-
tion to the idea that these mutations are positively se-
lected during tumorigenesis. SPN is normally produced
solely by white blood cells where it regulates functions
such as cell-cell adhesion, intracellular signaling, apop-
tosis, migration, and proliferation. Its ectopic expression
in solid tumors has been reported and proposed as a
target for immunotherapy [27]. In summary, in addition
to producing a very low rate of false positive results in
the detection of putative driver promoter elements,
OncodriveFML is able to identify already known and
putative interesting promoters with driver mutations,
even at very low mutational frequency. The whole list of
putative driver promoters (and other non-coding ele-
ments) appears in Additional file 3.
Among top-ranking FM biased 5′ UTR regions, we
found that of TBC1D12 (Fig. 3g). This gene encodes a
GTPase-activating protein for Rab family proteins. 5′
UTR mutations are recurrently found near the start
codon (Fig. 3h) and are detected in samples of different
tumor types. We detected it also as FM biased in
cohorts of the WG-608 dataset (Fig. 3i). The proximity
of the mutations to the start codon suggests that they
could have an effect on translational control. These mu-
tations were recently reported as significantly redundant
by [28], with 15 % of bladder tumor samples bearing
mutations using whole-exome data.
OncodriveFML uncovers genes with driver mutations in
splice intronic regions
We next analyzed with OncodriverFML the intronic re-
gions of coding genes, specifically, the 50 bps from
exon-intron boundary (intron-50 bps) using CADD as a
functional scoring framework to identify genes with
driver intron-splicing mutations. In the pan-cancer
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cohort, of the WG-505 dataset, OncodriveFML identifies
a shortlist of well-known tumor suppressor genes—TP53,
STK11, and NF1—as highly FM biased in their intron-
splicing mutations (Fig. 4a-b). TP53 contains 16 mutations
within the first 50 bps of its introns, seven of which appear
in breast cancer samples, while the others are distributed
across the cohorts of other tumor types (including
GBM, CRC, LUSC, SKCM, LUAD) (Fig. 4b). Interest-
ingly, eight of these mutations are within the first
2 bps of the intron-exon boundary. STK11 is a
serine/threonine-protein kinase known to act as a





Fig. 3 Results of the application of OncodriveFML to identify driver promoters and 5′ UTRs. The results of OncodriveFML are illustrated on mutations
found across the pan-cancer cohort (a–d) and the cohorts of lower grade gliomas (e, f) and bladder urothelial carcinomas (g–i) of the WG-505 dataset.
a, e, g QQ plots comparing the expected and observed distribution of FM bias p values of promoters and 5′ UTRs mutated in the respective cohorts.
b–d, h Mutation needle-plots of selected promoters and 5′ UTRs, with a zoom at mutations located in the proximity of the transcription start site (TSS),
or the 5 bps of the 5′ UTR closer to the CDS, respectively. f Comparison of the expression of two genes with significantly FM biased promoters in the
cohort of lower grade gliomas in samples with mutations in the promoter and unmutated samples. In the boxplots the gene expressions of the
mutated samples (on the left) is compared to those of unmutated samples (on the right). The expression values are reported in RPKM (Reads Per
Kilobase of transcript per Million mapped reads) on the y-axis and the number of samples (mutated and normal) in each set are indicated with dots on
the boxplots. The significance of the differential expression between mutated and non-mutated samples is reported at the top of each plot (Wilcoxon
rank-sum test). I. Significance of the 5′ UTR of the TBC1D12 gene across several cohorts of both the WG-505 and WG-608 datasets
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AMP-activated protein kinase (AMPK) family mem-
bers, thereby playing a role in various processes such
as cell metabolism, cell polarity, apoptosis, and DNA
damage response, often bearing inactivating mutations
in in lung adenocarcinomas [29, 30]. Most of the mu-
tations (4 out of 6) observed in the pan-cancer cohort
of the WG-505 dataset falling within the first 50 bps
of its introns indeed correspond to lung adenocarcin-
oma samples and all are in close proximity to the
intron-exon boundary (Fig. 4c).
OncodriveFML identifies putative driver 3′ UTRs
Next, we employed OncodriveFML to identify driver
genes upon mutations in their 3′ UTR regions. In this
case, we used the impact of mutations on RNA second-
ary structure computed by RNAsnp as FI score to com-
pute the FM bias of mutations [31]. In the pan-cancer
cohort of the WG-505 dataset, OncodriveFML identified
BORA and CHAF1B as putative driver genes from the
mutations in their 3′ UTR regions (Fig. 4d–h).
Mutations contributing to the computed FM bias for
CHAF1B in the WG-505 dataset appear in BRCA, CRC,
LUAD, and UCEC. On the other hand, in the pan-
cancer cohort of the WG-608 dataset, where it also
appears as significantly FM biased, mutations appear in
BRCA and STAD samples (Fig. 4e). CHAF1B is a chro-
matin assembly factor implicated in DNA replication
and DNA repair [32]. BORA is an Aurora kinase activa-
tor, involved in the maturation of the centrosome, the
assembly of the spindle and asymmetric protein
localization during mitosis [33].
OncodriveFML identifies putative lncRNAs
We next employed OncodriveFML to explore the poten-
tial of a group of lncRNAs collected from the literature
the biological functions of which have been established
[34–36] (Additional file 4). The mutated lncRNAs
among these (across cohorts in the WG-505 and WG-
608 datasets) were thus analyzed by OncodriveFML and
those significantly FM biased in at least one cohort
BORA (WG-505) (3’ UTR)
BRCA - chr13:73329969:G>A 
UCEC - chr13:73329970:T>C 
STAD - chr21:37789595:C>T 
BRCA- chr21:37789983:C>T STAD - chr21:37791264:C>T 
BRCA- chr21:37790156:C>T 
CHAF1B (WG-608) (3’ UTR)
UCEC- chr21:37789593:T>C 
CRC - chr21:37789595:C>T 
CRC - chr21:37789597:C>T 
CRC - chr21:37789630:T>A 


























































<BRCA (2) - LUSC - chr17:7577610:T>C (-2bp)
LUSC - chr17:7576960:A>T (-34bp)
CRC - chr17:7576843:G>A (+10bp)
SKCM - chr17:7578176:C>T (+1bp)
GBM (2) - chr17:7578555:C>T (-1bp)
BRCA - chr17:7578370:C>A (+1bp)
BRCA - chr17:7577498:C>T (+1bp) LUAD - chr17:7578556:T>A (-2bp)
LUSC - chr17:7578590:G>T (-36bp)
BRCA - chr17:7579622:C>A (-32bp)
BRCA (2) - chr17:7579653:T>C (-32bp)
CRC- chr17:7580766:G>A (-21bp)
STK11 (intron-splicing)
LUAD - chr19:1220370:A>C (-2bp)
LUAD -chr19:1221211:G>T (-1bp)
LUAD - chr19:1221947:G>A (-1bp)
HNSC - chr19:1220350:G>A (-22bp)
LUSC - chr19:1222008:G>A (+3bp)













Fig. 4 Results of the application of OncodriveFML to identify driver splice intronic regions and 3′ UTRs. The results of OncodriveFML are illustrated on
mutations found across the pan-cancer cohort of the WG-505 dataset. a, d QQ plots comparing the expected and observed distribution of FM bias p
values of splice intronic regions and 3′ UTRs mutated in the pan-cancer cohort. b, c, f–h Mutation needle-plots of selected splice intronic regions and 3′
UTRs. e Significance of the 3′ UTR of the CHAF1B gene across several cohorts of both the WG-505 and WG-608 datasets
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appear in Additional file 4. As in the case of 3′ UTRs,
we computed the FM bias using an FI metric that esti-
mates the impact of mutation on the RNA secondary
structure [31]. We found that MALAT1, a lncRNA gene
previously shown to be involved in tumorigenesis of
lung adenocarcinomas [37], exhibits a slightly significant
FM bias in cohorts of both the WG-505 (p value 0.0138
in KIRC) and the WG-608 (p value 0.0104 in pan-
cancer) datasets. In addition, we detected a higher than
expected accumulation of high functional impacting
somatic mutations in MIAT, a non-protein-coding
transcript associated with myocardial infarction in the
WG-505 dataset (p value 0.0281 in CRC and p value
0.0163 in pan-cancer).
OncodriveFML detects positive selection from the
sequence of a gene panel
Finally, we analyzed the list of somatic mutations de-
tected in a panel of genes sequenced at high coverage
across 234 biopsies of sun-exposed epidermis [38] to
illustrate the use of OncodriveFML on the task of de-
tecting genes under positive selection in the case when
most mutations in the sample are unavailable to the
method. OncodriveFML detects nine genes with a FM
bias q-value <0.1 (Fig. 5a and b), which include the five
genes identified by the authors using a modified dn/ds
approach (NOTCH1, NOTCH2, FAT1, TP53, RBM10)
and four other bona fide drivers of tumorigenesis
(NOTCH3, ARID2, KMT2D, ARID1A). Six out of these
nine genes are detected as drivers of cutaneous squa-
mous cell carcinoma (cSCC), the tumor type that
develops more frequently upon the malignization of
sun-exposed epidermis. The results reveal the potential
of OncodriveFML in identifying genes under positive
selection among those sequenced as part of a panel.
We have made OncodriveFML available to cancer gen-
omics researchers both to download and install the code
and to run through a web application (http://www.into-
gen.org/oncodrivefml).
Discussion
OncodriveFML introduces the construction of a local
mutational background to compute the FM bias of
genomic elements, a fundamental innovation which
differentiates it from other methods designed to pick up
signals of positive selection in genes across tumor sam-
ples. The local background model ensures that factors
influencing the mutation rate in the large-scale—such as
chromatin compaction or replication timing—do not
result in over or underestimation of the FM bias of any
genomic element. Other factors that affect the back-
ground mutation rate locally may still disturb the cal-
culation of the FM bias of genomic elements and, as
they are discovered, they should be incorporated into
this local modeling, as is the case of transcription factor
binding sites [39]. The combination of this local-
background-building approach and the compliance with
the mutational signature in the construction of the back-
ground model for the FM bias result in very fine-tuned
statistical test that produces a very low rate of false posi-
tives, effectively outperforming the current generation of
methods to detect driver genomic elements, both coding
and non-coding, as we have demonstrated in this article.
Furthermore, in principle OncodriveFML could also be
used to detect negative selection in the pattern of
somatic or germline variants observed across cohorts of
















































































































Fig. 5 Results of the application of OncodriveFML to the somatic mutations identified in a panel of genes in 234 biopsies of normal skin. a p value vs.
number of mutations of the 74 genes sequenced in the panel. Genes identified as significant with a q-value <0.1 (red dots) are indicated by their name
while genes identified as significant with a q-value <0.25 are marked as green dots. b Mutation needle-plots of the most significant genes
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Although the accuracy of OncodriveFML relies on the
predicted FI of mutations, these predictions need not be
accurate enough to correctly identify individual driver
variants, because the method computes the average FI of
mutations and compares it to the distribution of all
possible mutations in the region. Since FI scores are
more developed for coding mutations (as is the case
with CADD, which includes more information to score
coding mutations), OncodriveFML may currently lose
non-coding driver regions where the FI of mutations is
poorly assessed. Nevertheless, the development of new
methods aimed at scoring non-coding mutations as
more whole genomes of tumors are sequenced will
improve the quality of OncodriveFML in non-coding re-
gions. Furthermore, in all the results shown in this paper
in non-coding genomic elements, the FM bias has been
calculated exclusively based on nucleotide substitutions.
Finding a way of accurately scoring the FI of indels in
non-coding regions will probably contribute to uncover
new putative driver non-coding elements.
As the application of next generation sequencing tech-
nologies moves into the clinic, sequencing panels of
genes—or any genomic regions—rather than the whole
exomes or whole genomes of cohorts of tumors will
become the most frequent choice [40]. Sequencing gene
panels can also have important applications in research
to detect subsets of known cancer genes that act as
drivers or play other roles, such as drug resistance in spe-
cific cohorts of cancer patients. Here we have demonstrated
that due to the computation of the local FM bias of genes,
OncodriveFML is capable of detecting genes undergoing
positive selection even if the catalog of all exomic mutations
is not available for analysis. This capability will prove critical
to analyze the results of sequencing panels.
Conclusions
Here we describe OncodriveFML, a novel method able
to detect putative cancer driver genomic regions through
the computation of a local FM bias. As we have
shown, OncodriveFML is able to operate on both coding
and non-coding genomic regions, or any combination
thereof to reveal their involvement in tumorigenesis.
Furthermore, due to its unique local background model of
the FI of mutations it is able to detect signals of positive
selection in tumorigenesis when only the sequence of a
small portion of the genome is available, opening the op-




We analyzed a dataset of somatic mutations detected by
whole-exome sequencing (dataset WE-4482), two datasets
of somatic mutations detected by whole-genome
sequencing (datasets WG-608 and WG-505), and a dataset
of somatic mutations detected in a panel of genes se-
quenced at high coverage (dataset GP-234). The first data-
set (WE-4482) contains the somatic mutations of 19 cancer
types, the results of four of which (lung squamous cell
carcinoma, lung adenocarcinoma, skin cutaneous melan-
oma, and acute myeloid leukemia) are shown in Fig. 2. The
sources of the dataset are listed in Additional file 1. The
second dataset (dataset WG-608) contains the somatic mu-
tations of seven cancer types (breast invasive carcinoma,
chronic lymphocytic leukemia, liver cancer, lung adenocar-
cinoma, lymphoma B-cell, medulloblastoma, and pilocytic
astrocytoma) extracted from the work by Alexandrov et al.
[20] plus a supplementary stomach adenocarcinoma dataset
[41]. The third (dataset WG-505) contains the somatic mu-
tations of 14 cancer types determined by TCGA [12]. The
fourth dataset (dataset GP-234) contains the somatic muta-
tions detected in a panel of genes sequenced with high
coverage across 234 biopsies of sun-exposed epidermis
[38]. The datasets were filtered to discard all possible false
positives of the somatic mutations calling and we restricted
the analyses to single nucleotide substitutions (SNV) ex-
cluding from the study both insertions and deletions. The
number of samples and the number of mutations for each
dataset are listed in Additional file 1.
Definition of the coordinates of genomic elements
The genomic coordinates of both coding genes and
lncRNAs were obtained from the ENCODE website
(http://www.gencodegenes.org/), using Gencode re-
lease 19. Specifically, the coordinates of genes were
retrieved from ftp://ftp.sanger.ac.uk/pub/gencode/Gencode_
human/release_19/gencode.v19.annotation.gtf.gz. We only
consider CDS of genes where both the “gene_type”
and the “transcript_type” metadata were annotated as
“protein-coding.” We defined intronic splice sites as
50 bp regions at the edges of protein coding introns.
We removed from the datasets of UTRs all overlap-
ping coding regions and short intronic splice sites of
10 bp. In addition, we removed from 5′ UTRs any
overlap with 3′ UTRs. Promoter regions were defined
as sequences 2500 bp upstream the TSS of protein-
coding genes. We also removed from the dataset of
promoters any region previously annotated as protein-
coding (CDS), as untranslated region (3′ UTR and 5′
UTR), or as short intronic splice site. Overlapping ele-
ments of the same type (CDS of the same gene, UTRs of
the same gene, intronic splice sites of the same gene, or
promoters of the same gene) were merged together. Fi-
nally, we manually discarded genomic elements that show
any evidence of erroneous annotation.
The genomic coordinates of lncRNAs were obtained
from ftp://ftp.sanger.ac.uk/pub/gencode/Gencode_human/
release_19/gencode.v19.long_noncoding_RNAs.gtf.gz. We
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only considered the exons of lncRNAs where both the
“gene_type” and the “transcript_type” metadata were anno-
tated as “lincRNA.” We removed from the lncRNAs any
region previously annotated as protein-coding (CDS), as
untranslated region (3′ UTR and 5′ UTR), or as short
intronic splice site. and we merged together overlapping
exons of the same lncRNA.
Functional impact scoring metrics used in the analysis
The FI scores of all possible nucleotide changes in CDS
and promoters of genes were retrieved from the CADD
framework [16] version 1.0 (http://krishna.gs.washingto-
n.edu/download/CADD/v1.0/whole_genome_SNVs.tsv.gz).
This framework provides a score of deleteriousness for
every possible substitution of each nucleotide of the human
genome and can consequently be applied to every coding
or non-coding element of the genome. In the case of 3′
UTRs and lncRNAs, the FI for every possible substitution
in each position was calculated using RNAsnp [31] to
predict the impact of mutation on RNA secondary struc-
ture. The RNAsnp was executed with the “Mode 1” option
(with other parameters set to default) to compute the local
structural effect of mutations. For our analysis, we retrieved
the resultant Euclidean distance score, which represents
the difference between the base pair probabilities of
wild-type and mutant ensemble structures as the basis
to compute the FM bias.
OncodriveFML methodological details
OncodriveFML has the ability to use different scoring
frameworks, such as CADD [16] or RNAsnp [31]. Since
the method is independent of the scoring system used,
new scores can easily be incorporated to it as soon as
they become available.
For every coding or non-coding element OncodriveFML
proceeds with the following steps:
1. It first retrieves the FI score of all the mutations that
can occur in an element (for instance, a gene or a
UTR). The FI scores will vary depending on the
scoring framework used (CADD, RNAsnp, etc.).
2. It then calculates the mean of the FI scores of all the
observed mutations in the element across tumors.
3. It randomly takes from the pool of scores of all
possible nucleotide changes in the element under
analysis N samples of the same size as the number
of observed mutations. The higher the N, the more
resolution the derived empirical p values will have.
For every random-generated mutation, its FI score is
retrieved from the framework in use. The random
sampling procedure can vary depending on the
probability of each mutation to be sampled:
a) It can be assumed that all the random generated
mutations have equal probability to occur.
b) It can be assumed that the probability of each
mutation to occur is based on the mutational
signatures (i.e. tri-nucleotide composition)
observed in the dataset. For the analysis presented
in this study we computed matrices of tri-
nucleotide probabilities of the 96 possible changes
(e.g. probability of ATC to mutate to ACC,
probability of ATC to mutate to AGC, etc.). The
matrices are computed by counting all the
observed mutations in all the tumors. The
random sampling process will thus take into
account the different probabilities that each
mutation has to occur. For instance, if a dataset
show a higher frequency of the mutation ATT to
ACT, the same mutation will be more likely to be
sampled.
4. It computes the mean of each of the N random-
generated group of mutations. N random sampling
will generate a vector of N mean of FI scores.
5. It computes an empirical p value by comparing the
mean of the observed FI scores with the distribution
of means of the randomized FI scores. In brief, it
counts how many times the mean of the observed FI
scores is bigger than the means of the randomized
FI scores, and then normalizes this value by the
number of randomizations performed (N). For
instance, if 10,000 randomizations have been
computed (N is 10,000) and only two of these values
are bigger than the mean of the observed FI scores,
then the empirical p value would be 2/10,000, or
2*10–4. If the resulting p value is equal to 0, the
number of randomizations N can be increased in
order to gain a better p value resolution. The
obtained p value indicates how likely the mean of
the observed FI scores is expected by chance.
6. The resulting p values are then adjusted with a
multiple testing correction using the Benjamini–
Hochberg procedure. In the present study, we
adjusted the p values of regions mutated in at least
two samples in individual tumor types and five
samples in the pan-cancer dataset.
Comparison of OncodriveFML to other methods in the
identification of putative driver coding genes
The somatic mutations used in the comparison were
detected by whole-exome sequencing across the tumors
of 19 cohorts (4482 samples in total). The sources of the
data along with the number of samples and the number
of mutations of each cancer type are listed in Additional
file 1. The list of known cancer genes (CGC) [17] were
retrieved from the Catalog Of Somatic Mutations In
Cancer (COSMIC): sftp://sftpcancer.sanger.ac.uk/files/
grch38/cosmic/v72/cancer_gene_census.csv. MutSigCV
(version 1.4) was run using default parameters and using
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the full coverage file and the genes covariates provided
by the authors. OncodriveFM was run using default
parameters but setting the gene threshold (i.e. minimum
number of mutations per gene to compute the FM bias)
to 1. e-Driver was run with the mode option set to 1
(DOM). To compare OncodriveFML with the most
recent version of MutSigCV, not publicly available at the
time of writing, we obtained the list of significant genes
identified by MutSigCV as run directly by the authors
from the web http://tumorportal.org/. Since p values are
not provided, in this case it was not possible to compute
the proportion of known cancer genes among the top
ranking genes as in Fig. 2c, and instead we compared
the set of overlapping genes between both methods
(Additional file 2, section A). Further details of these
comparisons appear in the text in Additional file 2.
Generation of datasets of random mutations
For each dataset of somatic mutations analyzed, we
created a corresponding random dataset containing the
same number of samples and the same number of
somatic mutations (per sample) as the original dataset.
The simulated mutations were randomly repositioned
within windows of 50 Kb maintaining the original muta-
tional signature, i.e. the same tri-nucleotide composition.
The mutations whose reported reference allele was dif-
ferent from the corresponding position in the reference
genome (hg19) were not included in the simulation.
Needle plots
Figures 2, 3, 4, 5 show the linear distribution of muta-
tions along the sequence of a genomic element (gene,
UTR, promoter, etc.). The positions of the mutations
correspond to their relative location inside the element.
If an element is fragmented in different segments, these
are concatenated and the fragments are represented with
vertical dashed lines. The y-axis, and thus the height of
the dots, indicates how many mutations have been
observed in a given position (i.e. number of samples that
share the same mutation) and the color of the dots rep-
resents the functional impact (FI) score of each mutation
in the element. The color scale is normalized by the
range of scores presents in the element after considering
all the possible mutations. The “>” and “<” signs inside
the element denote its strand. The highest possible FI
score of each position of the element is represented
at the bottom of the needle plot. The p value of the
element is reported at the top-right of the plot.
Expression analysis
Precomputed expression data were retrieved from
Fredriksson et al. [12]. A detailed explanation of how
the expression level were determined is provided in
the original paper. In short, the authors obtained the
RNA-sequencing (RNA-seq) and copy-number data (Affy-
metrix SNP6) from the cgHub repository (https://cghub.
ucsc.edu). Gene expression level were subsequently deter-
mined by processing of raw sequencing data in BAM
format considering the coding and lncRNA subsets of the
GENCODE (v17) annotation and using HTSeq-count [42]
as described in Akrami et al. [43]. Copy-number ampli-
tudes were determined from segmented data (Affymetric
SNP6 platform) available from TCGA by considering
the minimum amplitude of all overlapping copy-number
segments for each gene.
The significance of the differential expression between
mutated and non-mutated samples was assessed using a
Wilcoxon rank-sum test. For a given gene and cancer type,
the test was performed only if at least 25 % of tumors had a
detectable expression (i.e. non-zero value). In addition, the
copy-number alteration data were taken into account and
copy number-altered samples were excluded from the ana-
lysis (i.e. absolute amplitude expressed in log2 scale >0.2).
After applying the filtering, we required at least ten
remaining samples per gene and cancer type in order to
compare the expression of the two groups.
Additional files
Additional file 1: An Excel file with a description of all datasets of
mutations used to test the performance of OncodriveFML in the detection
of putative driver genomic elements. Each tab in the file contains the
description of a separate dataset, with the first tab serving as a README.
(ODS 14 kb)
Additional file 2: A.pdf file containing a thorough description of methods
and results of the performance of OncodriveFML in comparison to other
common methods aim at the detection of driver genomic elements.
Section A describes the comparison with tools aimed at detection driver
coding genes; section B describes the same comparison in the case of
non-coding drivers detection tools. (PDF 4957 kb)
Additional file 3: An Excel file containing all significantly FM biased
genomic elements, both coding and non-coding detected across all
mutational datasets analyzed. The file is organized in tabs each
corresponding to the results in one dataset. (ODS 57 kb)
Additional file 4: An Excel file containing information on lncRNAs
probed for FM bias. The first sheet contains a README file with details on
the contents of the other two sheets. The second sheet contains the list
of all lncRNAs probed, a summary of their biological function, and the
original source from which we extracted them. The third sheet contains
the FM bias p value computed for each significantly FM biased lncRNA in
each cohort. (ODS 13 kb)
Abbreviations
CADD, combined annotation dependent depletion; CGC, Cancer Gene Census;
COSMIC, Catalog Of Somatic Mutations In Cancer; cSCC, cutaneous squamous
cell carcinoma; FI, functional impact; FM bias, functional mutations bias;
GP-234, dataset of a gene panel sequence of 234 tumor samples; TCGA, The
Cancer Genome Atlas; WE-4482, dataset of whole-exome sequence of 4482
tumor samples; WG-505, dataset of whole-genome sequence of 505 tumor
samples; WG-608, dataset of whole-genome sequence of 608 tumor samples
Acknowledgements
The results published here are in whole or part based upon data generated
by the TCGA Research Network: http://cancergenome.nih.gov/.
Mularoni et al. Genome Biology  (2016) 17:128 Page 11 of 13
Funding
We acknowledge funding from the Spanish Ministry of Economy and
Competitiveness (SAF2015-66084-R, MINECO/FEDER, UE), the Marató de TV3
Foundation, and the Spanish National Institute of Bioinformatics (INB). R.S. is
supported by an EMBO Long-Term Fellowship (ALTF 568-2014) co-funded by
the European Commission (EMBOCOFUND2012, GA-2012-600394) support
from Marie Curie Actions. A.G.-P. is supported by a Ramón y Cajal contract
(RYC-2013-14554).
Availability of data and material
The code of OncodriveFML is freely available via a Bitbucket repository (https://
bitbucket.org/bbglab/oncodrivefml), under a AGPL OSI-compliant license. Please
note that while the evolution of the method will determine changes of the code
in the aforementioned Bitbucket repository, the code of the OncodriveFML
version employed to generate the results presented in this article (v1.0) is available
at the zenodo repository (http://dx.doi.org/10.5281/zenodo.51834).
Authors’ contributions
NL-B and AG-P designed the method. LM and JD-P implemented and tested
it. RS computed the impact of mutations on RNA secondary structure. NL-B
and AG-P wrote the manuscript. LM prepared the figures and participated in
the writing of the manuscript. All authors read and approved the final
manuscript.
Competing interests
The authors declare that they have no competing interests.
Consent for publication
Not applicable.
Ethics approval and consent to participate
No ethics approval was required for the study, which is all based on publicly
available data.
Received: 11 February 2016 Accepted: 31 May 2016
References
1. Weinstein JN, Collisson EA, Mills GB, Shaw KRM, Ozenberger BA, Ellrott K, et
al. The Cancer Genome Atlas Pan-Cancer analysis project. Nat Genet. 2013;
45:1113–20.
2. ICGC. International network of cancer genome projects. Nature. 2010;464:993–8.
3. Gonzalez-Perez A, Mustonen V, Reva B, Ritchie GRS, Creixell P, Karchin R, et al.
Computational approaches to identify functional genetic variants in cancer
genomes. Nat Methods. 2013;10:723–9.
4. Lawrence MS, Stojanov P, Polak P, Kryukov GV, Cibulskis K, Sivachenko A, et al.
Mutational heterogeneity in cancer and the search for new cancer-associated
genes. Nature. 2013;499:214–8.
5. Gonzalez-Perez A, Lopez-Bigas N. Functional impact bias reveals cancer drivers.
Nucleic Acids Res. 2012;40:e169.
6. Tamborero D, Gonzalez-Perez A, Lopez-Bigas N. OncodriveCLUST: Exploiting
the positional clustering of somatic mutations to identify cancer genes.
Bioinformatics. 2013;29:2238–44.
7. Reimand J, Bader GD. Systematic analysis of somatic mutations in
phosphorylation signaling predicts novel cancer drivers. Mol Syst Biol.
2013;9:637.
8. Dees ND, Zhang Q, Kandoth C, Wendl MC, Schierding W, Koboldt DC, et al.
MuSiC: Identifying mutational significance in cancer genomes. Genome Res.
2012;22:1589–98.
9. Yates LR, Campbell PJ. Evolution of the cancer genome. Nat Rev Genet.
2012;13:795–806.
10. Polak P, Karlic R, Koren A, Thurman R, Sandstrom R, Michael S, et al. Cell-of-
origin chromatin organization shapes the mutational landscape of cancer.
Nature. 2015;518:360–4.
11. Weinhold N, Jacobsen A, Schultz N, Sander C, Lee W. Genome-wide analysis
of noncoding regulatory mutations in cancer. Nat Genet. 2014;46:1160–5.
12. Fredriksson NJ, Ny L, Nilsson JA, Larsson E. Systematic analysis of noncoding
somatic mutations and gene expression alterations across 14 tumor types.
Nat Genet. 2014;46:1–7.
13. Smith KS, Yadav VK, Pedersen BS, Shaknovich R, Geraci MW, Pollard KS, et al.
Signatures of accelerated somatic evolution in gene promoters in multiple
cancer types. Nucleic Acids Res. 2015;43:5307–17.
14. Lochovsky L, Zhang J, Fu Y, Khurana E, Gerstein M. LARVA: An integrative
framework for large-scale analysis of recurrent variants in noncoding
annotations. Nucleic Acids Res. 2015;43:8123–34.
15. Cheng DT, Mitchell T, Zehir A, Shah RH, Benayed R, Syed A, et al. MSK-IMPACT:
a hybridization capture-based next-generation sequencing clinical assay for
solid tumor molecular oncology. J Mol Diagn. 2015;17:251–64.
16. Kircher M, Witten DM, Jain P, O’Roak BJ, Cooper GM, Shendure J, et al. A
general framework for estimating the relative pathogenicity of human
genetic variants. Nat Genet. 2014;46:310–5.
17. Futreal PA, Coin L, Marshall M, Down T, Hubbard T, Wooster R, et al. A
census of human cancer genes. Nat Rev Cancer. 2004;4:177–83.
18. Porta-Pardo E, Godzik A. E-Driver: A novel method to identify protein
regions driving cancer. Bioinformatics. 2014;30:3109–14.
19. Lawrence MS, Stojanov P, Mermel CH, Robinson JT, Garraway LA, Golub TR,
et al. Discovery and saturation analysis of cancer genes across 21 tumour
types. Nature. 2014;505:495–501.
20. Alexandrov LB, Nik-Zainal S, Wedge DC, Aparicio Jr SA, Behjati S, Biankin AV,
et al. Signatures of mutational processes in human cancer. Nature. 2013;500:
415–21.
21. Huang FW, Hodis E, Xu MJ, Kryukov GV, Chin L, Garraway LA. Highly recurrent
TERT promoter mutations in human melanoma. Science. 2013;339:957–9.
22. Horn S, Figl A, Rachakonda PS, Fischer C, Sucker A, Gast A, et al. TERT promoter
mutations in familial and sporadic melanoma. Science. 2013;339:959–61.
23. Liu Y, Ni T, Xue Q, Lv L, Chen B, Cui X, et al. Involvement of p29/SYF2/
fSAP29/NTC31 in the progression of NSCLC via modulating cell proliferation.
Pathol Res Pract. 2015;211:36–42.
24. Song C, Gao Y, Tian Y, Han X, Chen Y, Tian DL. Expression of p114RhoGEF
predicts lymph node metastasis and poor survival of squamous-cell lung
carcinoma patients. Tumor Biol. 2013;34:1925–33.
25. Jacquemont C, Taniguchi T. Proteasome function is required for DNA
damage response and fanconi anemia pathway activation. Cancer Res.
2007;67:7395–405.
26. Gemoll T, Habermann JK, Becker S, Szymczak S, Upender MB, Bruch HP, et
al. Chromosomal aneuploidy affects the global proteome equilibrium of
colorectal cancer cells. Anal Cell Pathol. 2013;36:149–61.
27. Tuccillo FM, Palmieri C, Fiume G, de Laurentiis A, Schiavone M, Falcone C, et
al. Cancer-associated CD43 glycoforms as target of immunotherapy. Mol
Cancer Ther. 2014;13:752–62.
28. Araya CL, Cenik C, Reuter JA, Kiss G, Pande VS, Snyder MP, et al. Identification
of significantly mutated regions across cancer types highlights a rich
landscape of functional molecular alterations. Nat Genet. 2016;48:117–25.
29. Collisson EA, Campbell JD, Brooks AN, Berger AH, Lee W, Chmielecki J, et al.
Comprehensive molecular profiling of lung adenocarcinoma. Nature. 2014;
511:543–50.
30. Sanchez-Cespedes M, Parrella P, Esteller M, Nomoto S, Trink B, Engles JM, et
al. Inactivation of LKB1/STK11 is a common event in adenocarcinomas of
the lung. Cancer Res. 2002;62:3659–62.
31. Sabarinathan R, Tafer H, Seemann SE, Hofacker IL, Stadler PF, Gorodkin J.
RNAsnp: efficient detection of local RNA secondary structure changes
induced by SNPs. Hum Mutat. 2013;34:546–56.
32. Kaufman PD, Kobayashi R, Kessler N, Stillman B. The p150 and p60 subunits
of chromatin assembly factor I: a molecular link between newly synthesized
histones and DNA replication. Cell. 1995;81:1105–14.
33. Hutterer A, Berdnik D, Wirtz-Peitz F, Zigman M, Schleiffer A, Knoblich JA.
Mitotic activation of the kinase aurora-a requires its binding partner bora.
Dev Cell. 2006;11:147–57.
34. Ruiz-Orera J, Messeguer X, Subirana JA, Alba MM. Long non-coding RNAs as
a source of new peptides. Elife. 2014;3:e03523.
35. Prensner JR, Iyer MK, Balbin OA, Dhanasekaran SM, Cao Q, Brenner JC, et al.
Transcriptome sequencing across a prostate cancer cohort identifies PCAT-1,
an unannotated lincRNA implicated in disease progression. Nat Biotech. 2011;
29:742–9.
36. Khalil AM, Guttman M, Huarte M, Garber M, Raj A, Rivea Morales D, et al.
Many human large intergenic noncoding RNAs associate with chromatin-
modifying complexes and affect gene expression. Proc Natl Acad Sci U S A.
2009;106:11667–72.
37. Gutschner T, Hämmerle M, Diederichs S. MALAT1 - A paradigm for long
noncoding RNA function in cancer. J Mol Med. 2013;791–801.
Mularoni et al. Genome Biology  (2016) 17:128 Page 12 of 13
38. Martincorena I, Roshan A, Gerstung M, Ellis P, Van Loo P, McLaren S, et al.
High burden and pervasive positive selection of somatic mutations in
normal human skin. Science (80-). 2015;348:880–6.
39. Sabarinathan R, Mularoni L, Deu-Pons J, Gonzalez-Perez A, Lopez-Bigas N.
Nucleotide excision repair is impaired by binding of transcription factors to
DNA. Nature. 2016;532:264–7.
40. Lechner M, Frampton GM, Fenton T, Feber A, Palmer G, Jay A, et al.
Targeted next-generation sequencing of head and neck squamous cell
carcinoma identifies novel genetic alterations in HPV+ and HPV- tumors.
Genome Med. 2013;5:49.
41. Wang K, Yuen ST, Xu J, Lee SP, Yan HHN, Shi ST, et al. Whole-genome
sequencing and comprehensive molecular profiling identify new driver
mutations in gastric cancer. Nat Genet. 2014;46:573–82.
42. Anders S, Pyl PT, Huber W. HTSeq – A Python framework to work with high-
throughput sequencing data. Bioinformatics. 2015;31:166–9.
43. Akrami R, Jacobsen A, Hoell J, Schultz N, Sander C, Larsson E. Comprehensive
analysis of long non-coding RNAS in ovarian cancer reveals global patterns
and targeted DNA amplification. PLoS One. 2013;8:e80306.
•  We accept pre-submission inquiries 
•  Our selector tool helps you to find the most relevant journal
•  We provide round the clock customer support 
•  Convenient online submission
•  Thorough peer review
•  Inclusion in PubMed and all major indexing services 
•  Maximum visibility for your research
Submit your manuscript at
www.biomedcentral.com/submit
Submit your next manuscript to BioMed Central 
and we will help you at every step:
Mularoni et al. Genome Biology  (2016) 17:128 Page 13 of 13
